Spero Therapeutics Inc
Statements
Cash Flow
Spero Therapeutics Inc (SPRO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -5.4 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.5 | -9.2 | -7.0 | -8.9 | -11 | -11 | -12 | -8.6 | -5.5 | -14 | -11 | -12 | -9.7 | -17 | -23 | -25 | -21 | -16 | -15 | -17 | -5.0 | -27 | -28 | -23 | -1.0 | 44 | -13 | -19 | 16 | -17 | 5.9 | -19 | 13 | -23 | -4.0 | -18 | 17 | -8.4 | 16 | -5.4 | 20 | |
| 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.5 | -0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.2 | 0.2 | 0.3 | 0.3 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | 0.0 | 0.0 | – | – | – | |
| 0.1 | 0.1 | 0.1 | 0.1 | 0.9 | – | 0.6 | 0.7 | 0.7 | 0.8 | 0.9 | 0.9 | 1.0 | 0.9 | 1.1 | 1.2 | 1.2 | 1.4 | 2.0 | 2.2 | 2.3 | 2.9 | 3.2 | 1.3 | 2.1 | 2.5 | 2.2 | 1.9 | 1.9 | 2.0 | 2.0 | 2.1 | 2.2 | 1.5 | 1.6 | 0.7 | 1.0 | 1.0 | 1.1 | 0.8 | 4.0 | |
| – | -3.0 | -1.7 | -1.3 | 0.8 | -1.2 | 0.6 | 0.9 | 0.9 | 0.9 | 0.8 | 1.0 | 1.2 | 0.7 | 1.6 | 0.5 | 1.2 | 1.3 | 2.0 | 2.2 | 2.6 | 4.6 | 6.1 | 4.0 | 3.0 | 2.6 | 2.2 | 2.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 1.2 | -0.5 | 0.5 | 1.1 | -1.6 | -1.6 | -2.0 | 0.4 | 4.2 | -3.6 | -6.5 | 0.1 | 6.5 | 6.7 | -1.8 | -8.2 | -4.0 | 0.5 | 1.5 | -0.6 | 15 | -2.8 | -1.7 | 1.3 | 7.5 | 15 | -2.1 | -8.9 | 12 | -71 | 16 | -3.3 | 27 | -4.3 | 8.0 | -17 | 23 | -41 | 22 | 3.1 | 6.7 | |
| 0.2 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.4 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -0.2 | -0.3 | 0.0 | 0.0 | 0.0 | 0.0 | -23 | 5.0 | -73 | 7.3 | 25 | 25 | -16 | -4.1 | 28 | 18 | 3.9 | -40 | 3.0 | 11 | 17 | -23 | -16 | 50 | -0.1 | 34 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | 2.1 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | 8.5 | 78 | 78 | 0.0 | 0.0 | 0.0 | -0.2 | 70 | -0.2 | 1.6 | 9.0 | 0.0 | 5.6 | 30 | -2.0 | -19 | 4.8 | 4.3 | 0.0 | 1.8 | 28 | – | – | – | 10 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -54 | -54 | -54 | -54 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | 8.5 | 43 | -1.2 | -0.4 | -0.4 | 75 | -0.2 | 70 | -0.2 | 1.6 | 9.0 | 0.0 | 5.6 | 30 | 7.4 | 77 | 16 | 4.3 | 0.2 | 29 | 50 | 3.8 | -54 | 6.1 | 14 | 0.0 | 0.0 | 0.2 | 0.0 | – | – | – | 0.0 | – | – | – | – | – | – | – | |
| -6.7 | -1.0 | 36 | -10 | -11 | -11 | -35 | -3.8 | -8.2 | -6.4 | 15 | 22 | -26 | -16 | 35 | 1.0 | 60 | -40 | -8.2 | -5.5 | 41 | -0.3 | -40 | -27 | 5.0 | 59 | -13 | -19 | 16 | -17 | 5.9 | -19 | 13 | -23 | -4.0 | -18 | 17 | -8.4 | 16 | -5.4 | 20 | |
| -6.7 | -9.5 | -7.0 | -8.9 | -11 | -11 | -12 | -8.6 | -5.5 | -16 | -11 | -12 | -9.7 | -17 | -23 | -25 | -21 | -16 | -15 | -17 | -5.0 | -27 | -28 | -23 | -1.0 | 44 | -13 | -19 | 16 | -17 | 5.9 | -19 | 13 | -23 | -4.0 | -18 | 17 | -8.4 | 16 | -5.4 | 20 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.